



## Clinical trial results:

### Efficacy and Safety of Evinacumab in Adult Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis Summary

EudraCT number	2021-000437-13
Trial protocol	AT NL DE
Global end of trial date	15 February 2023

#### Results information

Result version number	v1 (current)
This version publication date	06 March 2024
First version publication date	06 March 2024

#### Trial information

##### Trial identification

Sponsor protocol code	R1500-HTG-20118
-----------------------	-----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Regeneron
Sponsor organisation address	777 Old Saw Mill River Road, Tarrytown, United States, 10591
Public contact	Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 8447346643, clinicaltrials@regeneron.com
Scientific contact	Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc, 9144093597 8447346643, donell.carey@regeneron.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 February 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	15 February 2023
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study is to determine the proportion of patients with elevated TGs, without FCS due to LoF mutations in LPL, and a history of HTG-associated AP\* who experience a recurrent episode of AP after treatment with evinacumab versus placebo.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Council for Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 July 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	United States: 18
Worldwide total number of subjects	21
EEA total number of subjects	1

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	21
From 65 to 84 years	0

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 40 participants were screened, of which 21 participants met the eligibility criteria and were randomized in 1:1 to receive either evinacumab or matched placebo. The sponsor terminated the study early due to enrollment issues.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Randomized 1:1

Arm type	Placebo
Investigational medicinal product name	Matching placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

First dose on day 1, with subsequent doses administered approximately every 4 weeks (Q4W)

<b>Arm title</b>	Evinacumab
------------------	------------

Arm description:

Participants received evinacumab 20 milligrams per kilogram (mg/kg) IV infusion Q4W starting from Day 1 up to 52 weeks.

Arm type	Experimental
Investigational medicinal product name	Evinacumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous use

Dosage and administration details:

First dose on day 1, with subsequent doses administered approximately every 4 weeks (Q4W)

<b>Number of subjects in period 1</b>	Placebo	Evinacumab
Started	10	11
Completed	7	5
Not completed	3	6
Subject Decision	-	4
Lost to follow-up	3	2

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description:	
Randomized 1:1	
Reporting group title	Evinacumab
Reporting group description:	
Participants received evinacumab 20 milligrams per kilogram (mg/kg) IV infusion Q4W starting from Day 1 up to 52 weeks.	

Reporting group values	Placebo	Evinacumab	Total
Number of subjects	10	11	21
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	10	11	21
From 65-84 years	0	0	0
85 years and over	0	0	0
Age Continuous			
Units: Years			
arithmetic mean	46.0	45.3	-
standard deviation	± 15.22	± 9.46	-
Sex: Female, Male			
Units: participants			
Female	3	2	5
Male	7	9	16
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	2	3	5
Not Hispanic or Latino	8	8	16
Unknown or Not Reported	0	0	0
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	1	1	2
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	1	1
White	9	9	18
More than one race	0	0	0
Unknown or Not Reported	0	0	0



## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Randomized 1:1	
Reporting group title	Evinacumab
Reporting group description:	
Participants received evinacumab 20 milligrams per kilogram (mg/kg) IV infusion Q4W starting from Day 1 up to 52 weeks.	

### Primary: Percentage of Participants with at least One Positively Adjudicated Acute Pancreatitis (AP) Episode

End point title	Percentage of Participants with at least One Positively Adjudicated Acute Pancreatitis (AP) Episode <sup>[1]</sup>
End point description:	
Adjudicated AP episode was determined by an independent acute pancreatitis adjudication committee (APAC). Suspected AP episodes was reviewed by 2 independent physicians. Percentage of participants with at least 1 positively adjudicated AP episode during the 52 weeks was reported.	
End point type	Primary
End point timeframe:	
Baseline to 52 weeks	
Notes:	
[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: No statistical analyses for this end point	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	11		
Units: Percentage				
number (not applicable)	10.0	27.3		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change in Apolipoprotein C3 (ApoC3) from Baseline to Week 52

End point title	Percent Change in Apolipoprotein C3 (ApoC3) from Baseline to Week 52
End point description:	
Apolipoproteins transport lipids through the body by binding with fat and cholesterol to form lipoproteins. ApoC3 was a component of very-low-density lipoproteins (VLDL), high-density lipoprotein (HDL), and triglyceride-rich chylomicrons and regulates lipid metabolism. Percent change in ApoC3 from Baseline to Week 52 was reported.	
End point type	Secondary
End point timeframe:	
Baseline to week 52	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[2]</sup>	1		
Units: Percent				
number (not applicable)		-73.78		

Notes:

[2] - Early termination of study due to low feasibility

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percent change in fasting triglycerides (TGs) - (from baseline to week 52)

End point title	Percent change in fasting triglycerides (TGs) - (from baseline to week 52)
End point description:	
End point type	Secondary
End point timeframe:	
Baseline to week 52	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[3]</sup>	1		
Units: Percent				
number (not applicable)		-92.88		

Notes:

[3] - Early termination of study due to low feasibility

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percent change in total cholesterol (TC) - (baseline to week 52)

End point title	Percent change in total cholesterol (TC) - (baseline to week 52)
End point description:	
End point type	Secondary
End point timeframe:	
Baseline to week 52	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[4]</sup>	1		
Units: Percent				
number (not applicable)		-57.62		

Notes:

[4] - Early termination of study due to low feasibility

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) - (from baseline to week 52)

End point title	Percent change in non-high-density lipoprotein cholesterol (non-HDL-C) - (from baseline to week 52)
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to week 52

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[5]</sup>	1		
Units: Percent				
number (not applicable)		-60.12		

Notes:

[5] - Early termination of study due to low feasibility

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent change in Apolipoprotein B48 (ApoB48) from baseline to week 52

End point title	Percent change in Apolipoprotein B48 (ApoB48) from baseline to week 52
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to week 52

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[6]</sup>	1		
Units: Percent				
number (not applicable)		-92.09		

Notes:

[6] - Early termination of study due to low feasibility

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent change in Apolipoprotein B100 (ApoB100) levels from baseline to week 52

End point title	Percent change in Apolipoprotein B100 (ApoB100) levels from baseline to week 52
End point description:	
End point type	Secondary
End point timeframe:	
Baseline to week 52	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[7]</sup>	1		
Units: Percent				
number (not applicable)		225.14		

Notes:

[7] - Early termination of study due to low feasibility

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change in Nuclear Magnetic Resonance (NMR)-Determined Particle Size and Number From Baseline to Week 52

End point title	Percent Change in Nuclear Magnetic Resonance (NMR)-Determined Particle Size and Number From Baseline to Week 52
End point description:	
End point type	Secondary
End point timeframe:	
Baseline to week 52	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[8]</sup>	0 <sup>[9]</sup>		
Units: Percent				
arithmetic mean (standard deviation)	()	()		

Notes:

[8] - Early termination of study due to low feasibility

[9] - Early termination of study due to low feasibility

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Independently Adjudicated Positive Episodes of Acute Pancreatitis (AP) Per Participant

End point title	Number of Independently Adjudicated Positive Episodes of Acute Pancreatitis (AP) Per Participant
End point description:	
End point type	Secondary
End point timeframe:	
Up to 52 weeks	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	11		
Units: Number of Episodes				
arithmetic mean (standard deviation)	0.1 (± 0.32)	0.4 (± 0.67)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

End point title	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
End point description:	
End point type	Secondary
End point timeframe:	
From start of study drug administration up to off drug follow-up (up to Week 72)	

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	11		
Units: Participants				
Participants with TEAEs	10	7		
Participants with Serious TEAEs	4	5		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With TEAEs Based on Severity

End point title	Number of Participants With TEAEs Based on Severity
-----------------	---

End point description:

AE was defined any untoward medical occurrence in a participant administered with a study drug, which does not necessarily had a causal relationship with this treatment. TEAEs are defined as AEs that developed or worsened during the treatment period. Severity of TEAEs was graded according to the following scale: Mild: Does not interfere in a significant manner with the participants normal functioning level, Moderate: Produces some impairment of functioning but is not hazardous to health and Severe: Produces significant impairment of functioning or incapacitation and is a definite hazard to the participants health.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study drug administration up to off drug follow-up (up to Week 72)

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	7		
Units: Participants				
number (not applicable)				
Participants with Mild TEAEs	3	3		
Participants with Moderate TEAEs	3	1		
Participants with Severe TEAEs	4	3		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Participants With Clinically Significant Changes from Baseline in Laboratory Parameters

End point title	Number of Participants With Clinically Significant Changes from
-----------------	---

## End point description:

Clinical laboratory parameters included biochemistry, hematology and urinalysis. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.

End point type	Secondary
----------------	-----------

## End point timeframe:

From start of study drug administration up to off drug follow-up (up to Week 72)

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10	11		
Units: Participants	0	0		

## Statistical analyses

No statistical analyses for this end point

**Secondary: Number of Participants With Positive Treatment-emergent Anti-Drug Antibodies (ADA)**

End point title	Number of Participants With Positive Treatment-emergent Anti-Drug Antibodies (ADA)
-----------------	--

## End point description:

Treatment-Emergent ADA was defined as any positive post baseline assay response when baseline results were negative or missing. Treatment-Emergent ADA responses were further classified as: Persistent (a positive result in the ADA assay detected in at least 2 consecutive post baseline samples separated by at least a 16-week post baseline period [based on] nominal sampling time], with no ADA-negative results in-between, regardless of any missing samples); Indeterminate (a positive result in the ADA assay at the last collection time point only, regardless of any missing samples); Transient (not persistent/indeterminate, regardless of any missing samples). Number of participants with positive treatment-emergent ADA response during Week 52 were reported.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline to Week 52

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	8	7		
Units: Participants				
number (not applicable)				
Persistent: Treatment-Emergent Response	0	0		
Transient: Treatment-Emergent Response	0	0		
Indeterminate: Treatment-Emergent Response	0	1		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Participants With Positive Neutralizing Antibodies (NAb)

End point title	Number of Participants With Positive Neutralizing Antibodies (NAb)
-----------------	--

End point description:

NAb positive was defined as presence of at least one positive nAb sample.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>		
Units: Participants				

Notes:

[10] - Early termination of study due to low feasibility

[11] - Early termination of study due to low feasibility

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change in Fasting High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52

End point title	Percent Change in Fasting High-density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 52
-----------------	---

End point description:

Percent Change in fasting HDL-C from Baseline to Week 52 was reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[12]</sup>	1		
Units: Percent change				
number (not applicable)		52.94		

Notes:

[12] - Early termination of study due to low feasibility

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change in Fasting Low Density Lipoprotein (LDL-C) From Baseline to Week 52

End point title	Percent Change in Fasting Low Density Lipoprotein (LDL-C) From Baseline to Week 52
-----------------	--

End point description:

LDL-C levels were determined in beta-quantification with ultracentrifugation method. Percent change in fasting LDL-C from Baseline to Week 52 was reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Week 52

End point values	Placebo	Evinacumab		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[13]</sup>	1		
Units: Percent				
number (not applicable)		695.00		

Notes:

[13] - Early termination of study due to low feasibility

## Statistical analyses

No statistical analyses for this end point

## Secondary: Concentration of Total Evinacumab in Serum

End point title	Concentration of Total Evinacumab in Serum <sup>[14]</sup>
-----------------	--

End point description:

Concentration of total evinacumab in serum by time at Pre-dose and End of Infusion were analyzed and reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose and End of Infusion (EOI) at Weeks 0, 4, 8, 12, 16, 20, 24, 32, 36, 40, 44, and 48; Pre-dose at Weeks 28 and 52

Notes:

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analyses for this end point

End point values	Evinacumab			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: milligrams per liter (mg/L)				
arithmetic mean (standard deviation)				
Week 0: Pre-dose	1.39 (± 4.40)			
Week 0: EOI (End of Infusion)	573 (± 95.7)			
Week 4: Pre-dose	97.6 (± 37.4)			
Week 4: EOI (End of Infusion)	638 (± 286)			
Week 8: Pre-dose	133 (± 88.6)			
Week 8: EOI (End of Infusion)	724 (± 123)			
Week 12: Pre-dose	158 (± 81.1)			
Week 12: EOI (End of Infusion)	749 (± 215)			
Week 16: Pre-dose	201 (± 68.7)			
Week 16: EOI (End of Infusion)	999.99 (± 999.99)			
Week 20: Pre-dose	999.99 (± 999.99)			
Week 20: EOI (End of Infusion)	999.99 (± 999.99)			
Week 24: Pre-dose	999.99 (± 999.99)			
Week 24: EOI (End of Infusion)	999.99 (± 999.99)			
Week 28: Pre-dose	999.99 (± 999.99)			
Week 32: Pre-dose	999.99 (± 999.99)			
Week 32: EOI (End of Infusion)	999.99 (± 999.99)			
Week 36: Pre-dose	99.1 (± 171)			
Week 36: EOI (End of Infusion)	999.99 (± 999.99)			
Week 40: Pre-dose	999.99 (± 999.99)			
Week 40: EOI (End of Infusion)	999.99 (± 999.99)			
Week 44: Pre-dose	999.99 (± 999.99)			
Week 44: EOI (End of Infusion)	999.99 (± 999.99)			
Week 48: Pre-dose	999.99 (± 999.99)			
Week 48: EOI (End of Infusion)	999.99 (± 999.99)			
Week 52: Pre-dose	999.99 (± 999.99)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Concentration of Total Angiopoietin-like 3 (ANGPTL3) in Serum

End point title	Concentration of Total Angiopoietin-like 3 (ANGPTL3) in
-----------------	---

End point description:

Concentration of total ANGPTL3 in serum by time were analyzed and reported.

End point type	Secondary
----------------	-----------

End point timeframe:

Pre-dose and End of Infusion (EOI) at Weeks 0, 4, 8, 12, 16, 20, 24, 32, 36, 40, 44, and 48; Pre-dose at Weeks 28 and 52

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: No statistical analyses for this end point

End point values	Evinacumab			
Subject group type	Reporting group			
Number of subjects analysed	10			
Units: mg/L				
arithmetic mean (standard deviation)				
Week 0: Pre-Dose	0.0907 (± 0.0272)			
Week 0: EOI (End of Infusion)	0.211 (± 0.0362)			
Week 4: Pre-Dose	0.248 (± 0.105)			
Week 4: EOI (End of Infusion)	0.306 (± 0.0992)			
Week 8: Pre-Dose	0.243 (± 0.0811)			
Week 8: EOI (End of Infusion)	0.298 (± 0.0831)			
Week 12: Pre-Dose	0.281 (± 0.0851)			
Week 12: EOI (End of Infusion)	0.322 (± 0.0672)			
Week 16: Pre-Dose	0.230 (± 0.0560)			
Week 16: EOI (End of Infusion)	999.99 (± 999.99)			
Week 20: Pre-Dose	999.99 (± 999.99)			
Week 20: EOI (End of Infusion)	999.99 (± 999.99)			
Week 24: Pre-Dose	999.99 (± 999.99)			
Week 24: EOI (End of Infusion)	999.99 (± 999.99)			
Week 28: Pre-Dose	999.99 (± 999.99)			
Week 32: Pre-Dose	999.99 (± 999.99)			
Week 32: EOI (End of Infusion)	999.99 (± 999.99)			
Week 36: Pre-Dose	0.162 (± 0.107)			
Week 36: EOI (End of Infusion)	999.99 (± 999.99)			
Week 40: Pre-Dose	999.99 (± 999.99)			
Week 40: EOI (End of Infusion)	999.99 (± 999.99)			

Week 44: Pre-Dose	999.99 (± 999.99)			
Week 44: EOI (End of Infusion)	999.99 (± 999.99)			
Week 48: Pre-Dose	999.99 (± 999.99)			
Week 48: EOI (End of Infusion)	999.99 (± 999.99)			
Week 52: Pre-Dose	999.99 (± 999.99)			

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From start of study drug administration up to off drug follow-up (72 weeks)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	Evinacumab 20 mg
-----------------------	------------------

Reporting group description:

Participants received evinacumab 20 mg/kg IV infusion Q4W starting from Day 1 up to 52 weeks.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Randomized 1:1

Serious adverse events	Evinacumab 20 mg	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 11 (45.45%)	4 / 10 (40.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic reaction			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
Pancreatitis acute			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	3 / 3	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	1 / 11 (9.09%)	2 / 10 (20.00%)	
occurrences causally related to treatment / all	1 / 1	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	<b>Evinacumab 20 mg</b>	<b>Placebo</b>	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 11 (72.73%)	8 / 10 (80.00%)	
<b>Vascular disorders</b>			
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
<b>General disorders and administration site conditions</b>			
Chest discomfort			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	

Fatigue subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
Investigations Pedal pulse decreased subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
Injury, poisoning and procedural complications Epicondylitis subjects affected / exposed occurrences (all)  Limb injury subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1  1 / 11 (9.09%) 1	0 / 10 (0.00%) 0  0 / 10 (0.00%) 0	
Nervous system disorders Headache subjects affected / exposed occurrences (all)  Dizziness subjects affected / exposed occurrences (all)  Somnolence subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1  0 / 11 (0.00%) 0  0 / 11 (0.00%) 0	1 / 10 (10.00%) 1  1 / 10 (10.00%) 1  1 / 10 (10.00%) 1	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
Gastrointestinal disorders			

Diarrhoea			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	
occurrences (all)	0	2	
Vomiting			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Pancreatic pseudocyst			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Nausea			
subjects affected / exposed	1 / 11 (9.09%)	2 / 10 (20.00%)	
occurrences (all)	1	2	
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Duodenitis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Abdominal pain			
subjects affected / exposed	4 / 11 (36.36%)	3 / 10 (30.00%)	
occurrences (all)	5	6	
Dyspepsia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	
occurrences (all)	0	1	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	
occurrences (all)	1	0	
Urticaria			

subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 3	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	
Infections and infestations Influenza subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	
Hand-foot-and-mouth disease subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	
Wound infection subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2	0 / 10 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
Cellulitis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
Bronchitis subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	
COVID-19 subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3	1 / 10 (10.00%) 1	
Metabolism and nutrition disorders Food intolerance subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	



**More information**

**Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 December 2021	Protocol Amendment 2

Notes:

---

**Interruptions (globally)**

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
15 February 2023	Study Termination	-

Notes:

**Limitations and caveats**

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The sponsor terminated the study early due to enrollment issues.
--

Notes: